Wapner on Avastin

Always interesting and engaging, Jessica Wapner has discussed the bevacizumab (Avastin) saga and a recent recommendation made to the FDA that the drug is not appropriate for the treatment of breast cancer. It is a difficult example because the drug is prohibitively expensive, will evoke a positive response in a relatively small proportion of patients, … Continue reading Wapner on Avastin

Wapner on drug ethics

Can Data Exclusivity Lead to Immortality? | Work In Progress Jessica Wapner talks about a recent article in Health Affairs that attempts to argue that increased data exclusivity will result in additional drug approvals and extended life expectancy. Clearly, Wapner is not swayed by the argument and notes that the authors have ties to industry … Continue reading Wapner on drug ethics